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The prevalence of pain in patients with sarcoma is not well documented. We investigated this in outpatients at a tertiary cancer
referral centre, assessing the adequacy of pain control and for risk factors leading to higher prevalence and severity of pain. 149
patients were surveyed. Patients with pain within the previous 7 days completed pain assessment tools (BPI, S-LANSS, PMI).
53% of patients had pain within the previous 7 days, and 25% had signiﬁcant pain. Of those with pain, 63% was inadequately
controlled and neuropathic pain was identiﬁed in 36%. Age, gender, tumour type, and the type of cancer treatment were not
signiﬁcant predictors of the prevalence or severity of the pain. Based on our results, patients with sarcoma should be actively
screened for pain and have regular reviews of their analgesic requirements.
1.Introduction
The prevalence of pain in cancer patients was recently inves-
tigated in a meta-analysis involving 52 studies [1]. Studies
from Europe, Asia, Australia, and USA have conﬁrmed that
cancer patients are repeatedly found to be in pain, both as
in—and outpatients, with undertreatment of their pain—
sometimes with no analgesia at all [2–8]. With a reported
overallprevalenceof52–72%[1,6,9],irrespectiveofstaging,
this is an issue which needs to be addressed on a global
scale. As pain prevalence is noted to vary amongst diﬀerent
cancer types [6], it is necessary to determine the prevalence
of pain in speciﬁc cancer types, to raise awareness amongst
clinicians, and to improve patient management.
Deandrea et al. [10] analysed 26 studies which used
the Pain Management Index (PMI) [11], a recognised tool
to evaluate the patient’s analgesic strategy based on WHO
guidelines [12]. They showed that 43% of patients had
a negative PMI score—thus deemed undertreated. Cancer
patients are living for longer and becoming long-term cancer
“survivors.” Cancer diagnosis now also occurs earlier with
the advancement of technology. Accurate assessment and
treatment of cancer pain is quite rightly becoming more
important,atanearlierstage,andforalongerperiodoftime.
With regards to pain prevalence related speciﬁcally to
sarcoma,thereisverylittledocumentationatall.Sarcomaisa
relatively rare, heterogenous type of cancer of the connective
tissue which may occur almost anywhere in the body. It is
not gender or age speciﬁc. The true incidence of sarcoma is
diﬃcult to ascertain as tumours are generally documented
with respect to their site of origin rather than tissue type.
The Sarcoma Trust/Sarcoma UK quotes 3200 cases in the UK
eachyear,orabout1%ofallcancerdiagnoses[13].TheRoyal
Marsden Hospital is a specialist referral centre for cancer in
London where we have around 750 patients with sarcoma
referred each year.
We undertook a cross-sectional, prevalence study of pain
in patients who attended the sarcoma outpatient clinics at
theRoyalMarsdenHospital.Inpatientswhohadanypainwe
attempted to specify the characteristics of their pain, includ-
ing severity, duration of pain, and the presence of break-
throughpain.Wequestionedtheadequacyofpaincontrolby
using the PMI, the perceived aetiology of their pain, and also
recorded the incidence of neuropathic pain in these patients.
Finally, we tested the hypothesis that particular risk factors
wereassociatedwithsigniﬁcantpain.Thestudyencompasses
the ﬁrst steps in the recommendations from the American
Pain Society [14]—to screen for the presence of pain and2 Sarcoma
complete comprehensive initial assessments—with the goal
of improving the quality of cancer pain management.
2. Methods
Ethics approval was granted by the Ethics Committee of the
Royal Marsden Hospita, and the study was registered with
the Hospital Committee for Clinical Research prior to the
study commencing. The research was carried out according
to Good Clinical Practice guidelines [15] and recommenda-
tions in the Declaration of Helsinki [16].
Patients were recruited from all sarcoma outpatient
clinics in our hospital over 6 months from May–November
2009.
Table 1 shows the inclusion criteria. The only exclusion
criterion was if the patient’s health would be compromised
by participation in the study.
2.1. Recruitment. All eligible consecutive patients attending
sarcoma outpatient clinics within the study period were
contacted via post or telephone a week before their clinic
appointment to inform them of the study. These patients
were then approached by the research team (independent
of the medical team) on the day of their appointment to
consent to the study. Those recruited ﬁlled out a screening
questionnaire, with the assistance of the research team.
2.2. Data Collection. The screening questionnaire collected
the following information.
Patient Demographics. Age, treatment history (from the
electronic patient records).
Prevalence of Pain. Pain in the previous 7 days, analgesic
medication, patients who had pain then had further assess-
ments of the characteristics and management of their pain.
Assessment of Pain. Duration of primary pain, presence
of breakthrough pain, aetiology of pain (possible causes
related to tumour pressure or inﬁltration, due to cancer
treatment or noncancer pain), the Brief Pain Inventory
(BPI) [17], researcher’s evaluation as to whether this was
nociceptive pain, neuropathic pain, or mixed nociceptive
and neuropathic pain, and the self-assessment version of
the Leeds Assessment of Neuropathic Symptoms and Signs
pain scale (S-LANSS) [18]. The BPI contains a collection
of Visual Analogue Scales (VAS) evaluating pain and its
impact on daily function. S-LANSS assesses the neuropathic
component by asking speciﬁc questions regarding the char-
acteristics of the pain. Both are well-validated tools of pain
self-assessment.
AdequacyofPainManagement. ThePainManagementIndex
(PMI) [11] is another widely used tool to evaluate the
congruence of the reported level of pain and the potency of
the prescribed analgesic by comparison to the World Health
Organisationanalgesicladder[12].Anegativescoreindicates
inadequate analgesic for that level of pain.
Table 1: Inclusion criteria for study.
All patients attending sarcoma outpatients who were:
(i) aged 18 and above,
(ii) diagnosed with sarcoma,
(iii) able to respond to an assessment written in English,
(iv) able to provide informed consent to participate in the study.
Alsoeligiblewere:patientswhohadreceivedanticancertreatments(includes
surgery, chemotherapy, radiotherapy and biological therapy) or were
currently receiving anticancer therapy, and patients with advanced or
metastatic disease.
Risk Factors. The following information was collected to
investigate whether they were predictors of pain: age, gender,
tumour type, staging, and treatment type (i.e., whether
surgery, radio-, chemotherapy, or biological therapy had
taken place). Binary logistic regression was used to identify
risk factors for pain. The relationship between the severity of
pain and the potential risk factors was investigated by using
ordinal regression. The analyses were performed using SPSS
version 17.
2.3.Outcomes. Theprimaryoutcomesweretheprevalenceof
“signiﬁcantpain”inallpatients—painscoreof5.0ormore—
and the proportion of patients with negative PMI, that is,
pain that was inadequately managed. The pain score was
a composite of the VAS for average pain, worst pain, least
pain, and pain right now. The secondary outcomes were the
prevalence of signiﬁcant pain association with risk factors as
mentioned above, the severity of pain associated with risk
factors,andtheproportionofpatientswithneuropathicpain
as determined by using S-LANSS.
2.4. Poststudy Surveillance. Patients inadequately treated for
pain, as determined by a negative PMI, were oﬀered advice
regardingongoingpainmanagement.Theyweregivenadvice
and contact details for our pain team, prescribed analgesia,
advised to seek further medical input from their GP, or
booked into our or patient’s own pain management clinic as
required.
3. Results
Demographics. 149 subjects were recruited from 228 eligible
patients. 79 did not participate due to reasons outlined in
Table 2. Patients were targeted in 22 clinics from May to
November2009,11surgical,7medicaloncology,4radiology.
The age range of recruited patients spanned from 19 to
98 years, median 62 years. The gender ratio was 44%
males (66/149) to 56% females (83/149). Tumour types are
listed in Table 3. 33/149 (22%) of subjects had metastatic
disease.
3.1. Pain Characteristics
Prevalence. The overall prevalence of any pain in the pre-
vious 7 days in the study population was 53% (79/149).Sarcoma 3
Using the Visual Analogue Scale (VAS) to score their worst
pain (range 1–10), 27 patients had mild pain (VAS 1–
4), 28 patients had moderate pain (VAS 5–7), and 24
patients described severe pain according to the VAS (8–10).
Signiﬁcant pain (≥5.0 by the composite pain score) occurred
in 25% of patients with pain (20/79), 95% conﬁdence
interval was 16–36.
Pain Duration. 48/79 (61%) of patients who reported pain
had background pain for over 3 months in duration. The
majority of the remainder (32%) had pain for more than 1
weekbutlessthan3months.3/79(4%)hadpainforlessthan
1 week. 3 patients described no background pain.
Breakthrough Pain. Breakthrough pain was problematic for
45 patients (57%). 31 patients (39%) had unresolved
breakthrough pain for more than 3 months. 7 patients had
breakthrough pain for more than 1 week, but less than 3
months.Theremaining7patientshadbreakthroughpainfor
less than 1 week.
Aetiology. The aetiology of their pain was discussed with the
patients. 7 patients felt that their pain was due to direct
pressure from the tumour, 1 due to metastatic disease.
50 patients had pain due to anticancer treatment, and 21
had pain from noncancer causes—17 musculoskeletal, 2
abdominal, 2 unspeciﬁed.
Adequacy of Pain Control. 50/79 patients (63%) who
reported pain were found to have a negative PMI—that is,
not adequately treated with regards to their pain.
Neuropathic Pain. From the description of their pain, 36
patients were assessed by the research team to have pain of
nociceptive origin, 7 neuropathic, and 36 mixed nociceptive
and neuropathic. Of those with a neuropathic component,
11 were taking adjuvant analgesics such as antidepressants
or anticonvulsants—3 from the purely neuropathic group, 8
from the mixed nociceptive and neuropathic pain group.
By using the S-LANSS questionnaire, 29 patients (36%)
ﬁt the neuropathic pain criteria (i.e., score ≥12). 11 of these
patients (38%) had signiﬁcant pain with a composite pain
score of ≥5 in the previous seven days. The worst VAS in the
previous seven days for 14 patients (48%) was ≥8.
3.2. Risk Factors. Age (comparing those greater to less than
60 years old), gender, tumour type, and cancer treatment
type were not implicated as predictors of pain by using the
binary logistic regression analysis (Table 4). The severity of
pain was also not found to be related to the above risk factors
by analysis with ordinal regression/χ2-testing (Table 5).
3.3. Poststudy Surveillance. Not all patients who had pain
wanted poststudy surveillance. No intervention was per-
formed in 35 patients (44%). 24/79 (31%) patients were
given advice by the researchers and given contact details of
our hospital pain team. 5 were advised to see their GP, 3 were
Table 2: Reasons for excluding patients.
Reason for exclusion Number of patients excluded
Missed at clinic 39
Refusal 16
Did not attend/cancelled 12
Histology benign 7
Histology unconﬁrmed sarcoma 3
Too upset to approach 1
Poor English 1
Total 79
Table 3: Types of tumour.
Type of tumour Number of patients
Angiosarcoma 3
Chondrosarcoma 1
Ewings sarcoma 1
Fibrosarcoma 16
Liposarcoma 30
Osteosarcoma 3
Other 80
Rhabdomyosarcoma 2
Soft tissue sarcoma 13
Total 149
Other:Leiomyosarcoma(21),GIST(11),Pleomorphic(11),Spindlecell(7),
Synovial (4), Dermatoﬁbrosarcoma (4), Fibromyosarcoma (3), Alveolar soft
tissue (1), GIST pancreas (1), Stromal (1), Myoxoid (1), Undiﬀerentiated
round cell (1), Peripheral nerve sheath (1), Endometrial stromal (1),
Myxoﬁbrosarcoma (1), Gastric (1), Small round cell (1), Mesenteric bowel
(1), Epithelioid (1), Giant cell (1), and Other unspeciﬁed (6).
Table 4: Risk factors associated with presence of pain.
Risk Factor P value
Age .173
Gender .322
Tumour type All values > .05
Chemotherapy .904
Biological therapy .880
Radiotherapy .445
Anticancer Surgery .203
(i) Amputation .792
(ii) Wide local excision .091
(iii) Surgery for recurrence .188
All P values > .05; hence all are not signiﬁcant.
prescribed an additional analgesic, and 13 were advised to
liaise with their local pain services, including 3 in our own
pain management clinics. Of the group for further contact
with pain management services, 9 had breakthrough pain for
more than 3 months and 9 scored positive for neuropathic
pain using the S-LANSS questionnaire. 2 patients required
referral back to their clinical team for further investigation of
the source of their pain.4 Sarcoma
Table 5: Risk factors assessed for prediction of pain severity.
Risk factor P value
Age (60 years as cutoﬀ) .651
Gender .964
Tumour type .817
All surgery .622
Amputation .251
Wide local excision .613
Surgery for recurrence .680
Chemotherapy .565
Biological therapy .923
Radiotherapy .959
Duration of pain .198
Cause of pain .743
All P values > .05; hence all are nonsigniﬁcant.
4. Discussion
In our paper, we found the prevalence of pain in our patients
with sarcoma to be 53%, which conﬁrms the overall ﬁgure
quoted in the meta-analysis of 52 studies of pain preva-
lence in cancer patients [1]. With 25% of patients having
signiﬁcant primary pain, it was clear that the management
of pain in these patients should be reassessed, and possibly
revised. 22% of our patient group had metastatic disease,
and this may be one reason for the ratio of our subjects with
signiﬁcant pain to be quite high, as patient with advanced
disease were previously found to have a higher incidence of
pain [1, 3, 4].
This high prevalence of pain was unfortunately accom-
panied by a similarly high incidence of inadequately treated
pain, as seen by 63% of patients having a negative PMI.
This again echoes current evidence that a high percentage
of cancer patients are still being undertreated for pain
[10], despite repeated guidelines from agencies such as the
WHO [12, 19, 20] and the Expert Working Group of the
European Association for Palliative Care [21], and assertions
that 90% of cancer pain should be manageable [20, 22].
Of note, the PMI does not take into account adjuvant
analgesics, so one should bear this in mind when considering
the results.
We did not speciﬁcally question patients regarding
pain syndromes, but rather any pain that they may have.
However, it is concerning that 61% patients had pain for
more than 3 months in duration. We know from other
studies that undertreatment of pain may result in patients
having increased morbidity [23, 24], increased prevalence
of depression and anxiety [25, 26], decreased enjoyment of
life [6, 27], poor sleep [28, 29], inability to self-care [6],
poor concentration, and poor personal interactions [6, 30].
Evidenceavailablesupportstheneedforprompttreatmentof
patients with acute pain, to prevent neuroplasticity, chronic
pain syndrome, and immune suppression [14]. It also has
massive socioeconomic costs including loss in productivity
[6, 31, 32], work days [25], and litigations [33].
Breakthrough pain was a diﬃculty for over half of our
patients with pain. Again, this has ramiﬁcations regarding
poor prognosis, reduced function, mood, and hospitalisa-
tions [34–37]. It should be identiﬁed and promptly treated
with regular reviews as part of the care package.
Nearly two-thirds of patients with pain felt that it was
as a result of anticancer treatment. With this in mind,
clinicians ought to be more vigilant regarding repeated
pain assessment and management alongside their anticancer
treatments. Patients are known to be reluctant to draw
attention to their pain due to many reasons [6, 23, 25, 38–
40] and need to be educated to do so, without fear that it
will compromise their anticancer treatment. One quarter of
patients had pain from noncancer sources. This conﬁrms
ﬁgures from previous studies [41] and also from patients in
other cancer groups [42–44], highlighting the importance of
a holistic approach to patient care.
A third of the patients with pain were assessed by the
research team to have a neuropathic component using S-
LANSS. A high percentage of those who scored positive
for neuropathic pain with the S-LANSS questionnaire rated
their pain to be signiﬁcant. Neuropathic pain clearly plays
a considerable role in this patient group, and wider use
of adjuvant analgesic therapy may be necessary to help to
control the pain.
We were unable to identify any predictors of presence of
any pain or severity of pain in our patient group. This may
be as a result of insuﬃcient sample size, or be due to the
aforementioned heterogeneity in sarcoma. There may also be
other factors not analysed in the study. Due to the rarity of
sarcoma, it would take some time to organise a larger study
to conﬁrm this. Suﬃce to say that it would be prudent for
clinicians to be aware of pain as a potential problem in all
patients with sarcoma.
5. Conclusion
We have shown pain to be a signiﬁcant problem in patients
who attend sarcoma outpatient clinics, irrespective of the
stage of their disease. Highlighted issues include severity of
pain, duration of pain, and presence of breakthrough pain.
Treatment of pain is generally inadequate and requires a full
initial assessment and regular reviews, alongside treatment
of the cancer. This should be a holistic approach to ensure
that patients who have pain from non-cancer causes are
also evaluated and referred as appropriate. Frequently, a
neuropathic component to the pain may make treatment
strategies complicated and adjuvants or specialist input may
be beneﬁcial. Future studies into pain prevalence in patients
with sarcoma would be worthwhile to identify risk factors. In
themeantime,itisuptothecliniciantobeawareofthepossi-
bility of a patient in pain who may be wary of drawing atten-
tion to the problem, resulting in long-lasting consequences.
Disclosure
The ﬁndings in this paper will be presented at the British
Sarcoma Group Conference 2011.Sarcoma 5
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